Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Reducing Ex Vivo Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells.

Ghassemi S, Nunez-Cruz S, O'Connor RS, Fraietta JA, Patel PR, Scholler J, Barrett DM, Lundh SM, Davis MM, Bedoya F, Zhang C, Leferovich J, Lacey SF, Levine BL, Grupp SA, June CH, Melenhorst JJ, Milone MC.

Cancer Immunol Res. 2018 Sep;6(9):1100-1109. doi: 10.1158/2326-6066.CIR-17-0405. Epub 2018 Jul 20.

PMID:
30030295
2.

Ex vivo Akt inhibition promotes the generation of potent CD19CAR T cells for adoptive immunotherapy.

Urak R, Walter M, Lim L, Wong CW, Budde LE, Thomas S, Forman SJ, Wang X.

J Immunother Cancer. 2017 Mar 21;5:26. doi: 10.1186/s40425-017-0227-4. eCollection 2017.

3.

A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.

Schneider D, Xiong Y, Wu D, Nӧlle V, Schmitz S, Haso W, Kaiser A, Dropulic B, Orentas RJ.

J Immunother Cancer. 2017 May 16;5:42. doi: 10.1186/s40425-017-0246-1. eCollection 2017.

4.

CAR-T Cell Therapy for Acute Lymphoblastic Leukemia: Transforming the Treatment of Relapsed and Refractory Disease.

Pehlivan KC, Duncan BB, Lee DW.

Curr Hematol Malig Rep. 2018 Oct;13(5):396-406. doi: 10.1007/s11899-018-0470-x. Review.

PMID:
30120708
5.

Treatment of advanced leukemia in mice with mRNA engineered T cells.

Barrett DM, Zhao Y, Liu X, Jiang S, Carpenito C, Kalos M, Carroll RG, June CH, Grupp SA.

Hum Gene Ther. 2011 Dec;22(12):1575-86. doi: 10.1089/hum.2011.070. Epub 2011 Sep 23.

6.

Antileukemic potency of CD19-specific T cells against chemoresistant pediatric acute lymphoblastic leukemia.

Dolnikov A, Shen S, Klamer G, Joshi S, Xu N, Yang L, Micklethwaite K, O'Brien TA.

Exp Hematol. 2015 Dec;43(12):1001-1014.e5. doi: 10.1016/j.exphem.2015.08.006. Epub 2015 Sep 16.

PMID:
26384559
7.

Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.

Li S, Siriwon N, Zhang X, Yang S, Jin T, He F, Kim YJ, Mac J, Lu Z, Wang S, Han X, Wang P.

Clin Cancer Res. 2017 Nov 15;23(22):6982-6992. doi: 10.1158/1078-0432.CCR-17-0867. Epub 2017 Sep 14.

8.

Versatile strategy for controlling the specificity and activity of engineered T cells.

Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, Rodgers DT, Pugh HM, Singer O, Sun SB, Fonslow BR, Kochenderfer JN, Wright TM, Schultz PG, Young TS, Kim CH, Cao Y.

Proc Natl Acad Sci U S A. 2016 Jan 26;113(4):E450-8. doi: 10.1073/pnas.1524193113. Epub 2016 Jan 12.

9.

Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system.

Zhang W, Jordan KR, Schulte B, Purev E.

Drug Des Devel Ther. 2018 Oct 5;12:3343-3356. doi: 10.2147/DDDT.S175113. eCollection 2018.

10.

Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.

Tomuleasa C, Fuji S, Berce C, Onaciu A, Chira S, Petrushev B, Micu WT, Moisoiu V, Osan C, Constantinescu C, Pasca S, Jurj A, Pop L, Berindan-Neagoe I, Dima D, Kitano S.

Front Immunol. 2018 Feb 19;9:239. doi: 10.3389/fimmu.2018.00239. eCollection 2018. Review.

11.

Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.

Oelsner S, Wagner J, Friede ME, Pfirrmann V, Genßler S, Rettinger E, Buchholz CJ, Pfeifer H, Schubert R, Ottmann OG, Ullrich E, Bader P, Wels WS.

Int J Cancer. 2016 Oct 15;139(8):1799-809. doi: 10.1002/ijc.30217. Epub 2016 Jun 11.

12.

CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.

Singh N, Frey NV, Grupp SA, Maude SL.

Curr Treat Options Oncol. 2016 Jun;17(6):28. doi: 10.1007/s11864-016-0406-4. Review.

PMID:
27098534
13.

Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia.

Magnani CF, Mezzanotte C, Cappuzzello C, Bardini M, Tettamanti S, Fazio G, Cooper LJN, Dastoli G, Cazzaniga G, Biondi A, Biagi E.

Hum Gene Ther. 2018 May;29(5):602-613. doi: 10.1089/hum.2017.207. Epub 2018 Apr 16.

PMID:
29641322
14.

Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.

An N, Tao Z, Li S, Xing H, Tang K, Tian Z, Rao Q, Wang M, Wang J.

Oncotarget. 2016 Mar 1;7(9):10638-49. doi: 10.18632/oncotarget.7079.

15.

Co-Expansion of Cytokine-Induced Killer Cells and Vγ9Vδ2 T Cells for CAR T-Cell Therapy.

Du SH, Li Z, Chen C, Tan WK, Chi Z, Kwang TW, Xu XH, Wang S.

PLoS One. 2016 Sep 6;11(9):e0161820. doi: 10.1371/journal.pone.0161820. eCollection 2016.

16.

Open access? Widening access to chimeric antigen receptor (CAR) therapy for ALL.

Ghorashian S, Amrolia P, Veys P.

Exp Hematol. 2018 Oct;66:5-16. doi: 10.1016/j.exphem.2018.07.002. Epub 2018 Jul 20. Review.

PMID:
30031849
17.

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.

Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, La Perle K, Quintás-Cardama A, Larson SM, Sadelain M.

Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5426-35. Epub 2007 Sep 12.

18.

Induction of a central memory and stem cell memory phenotype in functionally active CD4+ and CD8+ CAR T cells produced in an automated good manufacturing practice system for the treatment of CD19+ acute lymphoblastic leukemia.

Blaeschke F, Stenger D, Kaeuferle T, Willier S, Lotfi R, Kaiser AD, Assenmacher M, Döring M, Feucht J, Feuchtinger T.

Cancer Immunol Immunother. 2018 Jul;67(7):1053-1066. doi: 10.1007/s00262-018-2155-7. Epub 2018 Mar 31.

PMID:
29605883
19.

Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants.

Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S.

Cancer Immunol Res. 2017 Jul;5(7):571-581. doi: 10.1158/2326-6066.CIR-16-0376. Epub 2017 May 26.

20.

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells.

Kueberuwa G, Zheng W, Kalaitsidou M, Gilham DE, Hawkins RE.

J Vis Exp. 2018 Oct 16;(140). doi: 10.3791/58492.

Supplemental Content

Support Center